Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 359, Issue 1, pp 48–52 | Cite as

Characterization of cannabinoid receptors coupled to vasorelaxation by endothelium-derived hyperpolarizing factor

  • David Harris
  • David A. Kendall
  • M. D. Randall
Original article

Abstract

We have recently proposed that an endogenous cannabinoid may be an endothelium-derived hyperpolarizing factor (EDHF), and we have now characterized the cannabinoid receptors mediating these responses. EDHF-mediated vasorelaxations to carbachol (ED50=3.26±0.57 nmol; the maximum relaxation, R max=87.0±2.5%) were opposed by the selective cannabinoid CB1 antagonist, LY320135: at 2 µM ED50 for carbachol was 10.4±2.6 nmol and R max was 66.9±6.2%, at 10 µM ED50 was 15.9±4.0 nmol and R max was 34.0±4.3%. However, these responses were unaffected by another putative CB1 ligand, AM630 (10 µM), or a CB2 selective antagonist, SR144528 (100 nM–1 µM). None of the antagonists influenced vasorelaxation to either the potassium channel activator levcromakalim or sodium nitroprusside. Coupled to our previous observation that the CB1 receptor antagonist SR141716A opposes EDHF-mediated relaxation, the present observations point to the involvement of a cannabinoid receptor, which may be CB1 or CB1-like, in EDHF-mediated vasorelaxation.

Key words Endothelium Endothelium-derived hyperpolarizing factor (EDHF) Cannabinoids LY320135 AM630 SR144528 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • David Harris
    • 1
  • David A. Kendall
    • 1
  • M. D. Randall
    • 1
  1. 1.School of Biomedical Sciences, University of Nottingham Medical School, Queen’s Medical Centre, Nottingham NG7 2UH, UK e-mail: michael.randall@nottingham.ac.uk, Fax: +44-115-9709259GB

Personalised recommendations